Time to dry analysis of brolucizumab vs aflibercept in patients with neovascular AMD: 96-week data from the HAWK and HARRIER trials

Ian McAllister, Eric Souied, Carl Regillo, David Brown, Frank Holz, David Tanzer, Jahangir Alam, Pravin Dugel

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	149-150
Number of pages	2
Journal	Clinical and Experimental Ophthalmology
Volume	47
Publication status	Published - Nov 2019

Cite this

@article{f77e50fea338461b8ce9bd2e6275662e,

title = "Time to dry analysis of brolucizumab vs aflibercept in patients with neovascular AMD: 96-week data from the HAWK and HARRIER trials",

author = "Ian McAllister and Eric Souied and Carl Regillo and David Brown and Frank Holz and David Tanzer and Jahangir Alam and Pravin Dugel",

year = "2019",

month = nov,

language = "English",

volume = "47",

pages = "149--150",

journal = "Clinical and Experimental Ophthalmology",

issn = "1442-6404",

publisher = "John Wiley & Sons",

}

TY - JOUR

T1 - Time to dry analysis of brolucizumab vs aflibercept in patients with neovascular AMD

T2 - 96-week data from the HAWK and HARRIER trials

AU - McAllister, Ian

AU - Souied, Eric

AU - Regillo, Carl

AU - Brown, David

AU - Holz, Frank

AU - Tanzer, David

AU - Alam, Jahangir

AU - Dugel, Pravin

PY - 2019/11

Y1 - 2019/11

M3 - Abstract/Meeting Abstract

SN - 1442-6404

VL - 47

SP - 149

EP - 150

JO - Clinical and Experimental Ophthalmology

JF - Clinical and Experimental Ophthalmology

ER -